# Safety and Immunogenicity of a Live-attenuated Vaccine Against Respiratory Syncytial Virus in Elderly Volunteers

> **NCT04295070** · PHASE1 · COMPLETED · sponsor: **Codagenix, Inc** · enrollment: 36 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** CodaVax-RSV
- **BIOLOGICAL:** Normal saline

## Key facts

- **NCT ID:** NCT04295070
- **Lead sponsor:** Codagenix, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-10
- **Primary completion:** 2021-03-06
- **Final completion:** 2021-05-26
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2021-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04295070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04295070, "Safety and Immunogenicity of a Live-attenuated Vaccine Against Respiratory Syncytial Virus in Elderly Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04295070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*